Hair loss showdown: spray or pill? new study to find out
NCT ID NCT07273799
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares two forms of minoxidil—a topical spray and an oral pill—for treating androgenetic alopecia (common hair loss) in 200 men and women aged 18 to 50. Over 6 months, researchers will measure hair regrowth, shedding, and side effects. Participants will use either the spray or the pill, along with a placebo of the other form, to see which works better and is safer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
minoxidil
What this could lead to
If this trial succeeds, it could show that oral minoxidil is a safe and effective alternative to the topical spray for treating hair loss.
What could go wrong
This is a Phase 3 trial, but it is not yet recruiting and only includes 200 people. Oral minoxidil may cause more side effects like dizziness or unwanted hair growth, and results may not apply to everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANDROGENIC ALOPECIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.